Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
Journal
Scientific Reports
Journal Volume
11
Journal Issue
1
Pages
23473
Date Issued
2021
Author(s)
Huang C.-F.
Kuo H.-T.
Chang T.-S.
Lo C.-C.
Hung C.-H.
Huang C.-W.
Chong L.-W.
Cheng P.-N.
Yeh M.-L.
Peng C.-Y.
Cheng C.-Y.
Huang J.-F.
Bair M.-J.
Lin C.-L.
Yang C.-C.
Wang S.-J.
Hsieh T.-Y.
Lee T.-H.
Lee P.-L.
Wu W.-C.
Lin C.-L.
Su W.-W.
Yang S.-S.
Wang C.-C.
Hu J.-T.
Mo L.-R.
Chen C.-T.
Huang Y.-H.
Chang C.-C.
Huang C.-S.
Chen G.-Y.
Kao C.-N.
Tai C.-M.
Lee M.-H.
Tsai P.-C.
Dai C.-Y.
Lin H.-C.
Chuang W.-L.
Chen C.-Y.
Tseng K.-C.
Yu M.-L.
Abstract
The study evaluated the real-world treatment outcomes of Glecaprevir/pibrentasvir (GLE/PIB) including effectiveness, safety and healthcare resource utilization based on a nation-wide registry in Taiwan. The Taiwan HCV Registry (TACR) is a nation-wide platform organized and supervised by the Taiwan Association for the Study of the Liver. Data were analyzed for patients treated with GLE/PIB, including 3144 patients who had treatment outcome available. The primary endpoint was sustained virological response (SVR12, undetectable HCV RNA throughout 12 weeks of end-of-treatment). The overall SVR12 rate was 98.9% (3110/3144), with 98.8%, 99.4% and 100% in patients receiving 8 weeks, 12 weeks, and 16 weeks of GLE/PIB respectively. The SVR12 rate in the treatment-na?ve cirrhotic patients receiving 8 weeks of GLE/PIB was 98.2% (108/110). The most common AEs were fatigue (7.5%), pruritus (6.7%) and dizziness (1.5%). The mean number of outpatient visits during the GLE/PIB was 5.94 visits for patients treated with 8 weeks, significantly different from the patients treated with 12 weeks of GLE/PIB (6.90 visits). The results support the effectiveness and safety of GLE/PIB treatment in real-world clinical practice, and provide further evidence that the shorter, 8-week GLE/PIB regimen is effective and cost-saving.
SDGs
Publisher
Nature Research
Type
journal article